C2i Limited (trading as C2i - Cell Culture Intelligence)
Automated organoid culture systems designed for scalable and reproducible growth of human organoids, facilitating advanced research and drug discovery.
- CEO / Founder
- Dr. Yuguo Lei
- Team Size
- 11-50
- Stage
- Commercial
- Total Funding
- $4M
- Latest Round
- Series A
- Key Investors
- Veracyte Inc., Hong Kong-based VCs, Government-affiliated innovation funds
Technology & Products
Key Products
["Automated Organoid Culture System","AI-driven Real-time Monitoring Software","Customized Bioreactors for Various Organoid Types"]
Technological Advantage
Enables high-throughput, reproducible organoid manufacturing, reducing variability and cost compared to manual processes.
Differentiation
Value Proposition
Automates and standardizes the complex process of organoid culture to increase throughput, ensure consistency, and reduce human error, thereby accelerating preclinical research and drug development.
How They Differentiate
Focus on fully automated, large-scale production of organoids for industrial-scale drug screening, as opposed to smaller-scale, microfluidic organ-on-a-chip systems.
Market & Competition
Target Customers
Pharmaceutical companies, biotechnology firms, contract research organizations (CROs), and academic research institutions.
Industry Verticals
["Pharmaceuticals","Biotechnology","Academic & Clinical Research"]
Competitors
Emulate Inc.; Mimetas BV; Greiner Bio-One
Growth & Milestones
Growth Metrics
Not publicly disclosed
Major Milestones
["Founded in 2018","Established in Hong Kong Science Park","Developed and patented core automation technology","Launched Hong Kong's first automated organoid culture system in collaboration with Hitachi High-Tech Corporation in 2024"]
Notable Customers
Hitachi High-Tech Corporation (collaborative case study)